 This study is an open-label pilot trial in which all patients will receive AST-120 in 2 g sachets three times a day to be taken between meals at 10:00 am, 3:00 pm, and immediately before going to bed for 4 complete weeks. AST-120 is a tasteless, odorless, oral preparation. To take the product, patients will tear open the sachets, drop the contents directly on their tongue and wash it down with 8 ounces of water. All antibiotics, probiotics and nutritional agents must have been discontinued for at least 2 weeks prior to study entry. For purposes of this trial response is defined as a or 3 point reduction in the 18-point PDAI scoring system. Remission is defined as a PDAI score 7. 